Open for inclusion

KCP-330-005A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 (Selinexor) in Patients with Advanced Gynaecologic Malignancies

Cancer type: Ovarian cancer

Phase: II

Principal Investigator: Mau-Sørensen Morten

Country: DK

Keywords: Denmark, Rigshospitalet, SINE

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02025985?term=KCP-330-005&rank=1